Monday, November 15, 2010

FDA approves Halaven (eribulin mesylate) for the treatment of metastatic breast cancer

The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate) to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease.

Halaven is a synthetic form of a chemotherapeutically active compound derived from the sea sponge Halichondria okadai. This injectable therapy is a microtubule inhibitor, believed to work by inhibiting cancer cell growth. Before receiving Halaven, patients should have received prior anthracycline- and taxane-based chemotherapy for early or late-stage breast cancer.

Halaven is marketed by Woodcliff Lakes, N.J. -based Eisai Inc.

Read more on the FDA website.

1 comment:

  1. This really is a great help for women who suffered such a deadly cancer.

    ReplyDelete

Blog Widget by LinkWithin